Astellas Pharma Inc. v. Lupin Ltd.
1:24-cv-00939
Overview
Parties
Defendant
Lupin Pharmaceuticals, Inc. Operating Company
Represented By
2 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Phillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., DE
Lupin Ltd. Operating Company
Represented By
7 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Phillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., DE
Plaintiff
Astellas Pharma Global Development, Inc. Operating Company
Represented By
5 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Astellas Ireland Co., Ltd. Operating Company
Represented By
5 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Astellas Pharma Inc. Operating Company
Represented By
5 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 6 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 12,059,409 B1 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,133,808 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2016018427 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,842,780 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2021032238 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2023184482 | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US12059409
Pharmaceutical composition for modified release
|
Filed: 2024-03-22
Issued: 2024-08-13
|
Active (17.3 yrs remaining)
Expires: 2044-03-22
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. Standard Maintenance Fee Schedule Tracked (3.5, 7.5, 11.5 Years).
Procedural Motions & Interlocutory Orders
Total Motions
3
Dispositive
0
Granted
0
Denied
0
Pending / Review
2
Motions by Category
Key Dispositive Motions & Rulings